Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Sanofi clinches $2 billion vaccines deal with Translate Bio

Published 23/06/2020, 06:16
© Reuters. Sanofi logo is seen in Paris
SASY
-
TBIO_old
-

By Sudip Kar-Gupta

PARIS (Reuters) - French drugmaker Sanofi (PA:SASY) has agreed a potential $2 billion (£1.6 billion) deal with U.S. biotech company Translate Bio (O:TBIO) to make vaccines, expanding their collaboration in development of an inoculation against COVID-19.

The deal strengthens Sanofi's credentials in a market engaged in a frantic race to find a safe and effective vaccine against the coronavirus disease that has killed more than 472,000 worldwide.

The companies said they would expand their partnership to develop a wide range of mRNA vaccines. The mRNA (messenger ribonucleic acid) technology, an area of Translate Bio expertise, instructs human cells to make specific proteins that produce an immune response to a disease.

The deal will give Sanofi about 7.2% of Translate Bio and exclusive worldwide rights to develop, manufacture and sell infectious disease vaccines using the U.S. company's technology.

Sanofi expects its mRNA COVID-19 vaccine candidate to enter clinical trials by the end of the year and, if successful, gain regulatory approval in the second half of 2021.

The group is also working on another COVID-19 vaccine with Britain's GlaxoSmithKline (L:GSK), targeting approval in the first half of next year.

Translate Bio, meanwhile, will receive an upfront payment of $425 million, comprising $300 million in cash and a common stock investment of $125 million through a private placement at $25.59 per share - a 57.6% premium to Monday's closing price of $16.24.

The U.S. biotech specialist will also be eligible for further potential milestone and other payments of up to $1.9 billion, the companies said.

The deal makes Sanofi its fourth-largest shareholder, Refinitiv data shows.

© Reuters. FILE PHOTO: The French drugmaker's vaccine unit Sanofi Pasteur plant in Marcy-l'Etoile

Sanofi last month sold most of its 20.6% stake in U.S. partner Regeneron (O:REGN) for more than $11 billion and said it would use the money for innovation and general growth, with financial sources telling Reuters they expected the group to engage in a series of smaller deals rather than a large acquisition.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.